Medication info
Rosuvastatin Calcium 5 mg (Rosuvastatin Calcium Tablet)

Rosuvastatin Calcium 5 mg (Rosuvastatin Calcium Tablet)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
30 tablets/PTP [(10 tablets/PTP x 3)], 30 tablets/bottle
Approval status
Active

MFDS item code 201000982 · Approved 2010.01.28 · Insurance code 643305640

Summary

Main use
Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased up to a maximum of 20 mg daily. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.
Child dose
Aged 10 to 17 years: The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) Younger than 10 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
  • smoking
  • family history of early coronary heart disease
  • risk of stroke
View approved original text

This medication serves as an adjunct to diet in the management of primary hyperlipidemia and mixed dyslipidemia in patients whose conditions are not adequately controlled by diet and exercise alone. It is also used in conjunction with other lipid-lowering therapy in patients with homozygous familial hypercholesterolemia. By lowering total cholesterol and LDL cholesterol levels, it delays the progression of atherosclerosis and is also helpful in treating familial hypercholesterolemia in children and adolescents. Additionally, it aids as an adjunct to diet in patients with primary dysbetalipoproteinemia and helps reduce the risk of stroke, myocardial infarction, and revascularization in high-risk cardiovascular patients with elevated high-sensitivity C-reactive protein levels. Thus, it is effectively used in treating patients with various forms of dyslipidemia and cardiovascular risk factors.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased up to a maximum of 20 mg daily. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.

Child dose

Aged 10 to 17 years: The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) Younger than 10 years: Safety and efficacy have not been established.

Precautions

This drug should not be used in certain patients. It must not be administered to those with allergies to its components, severe liver impairment, muscle disorders, patients taking specific medications, severely impaired renal function, women who are pregnant or breastfeeding, and those at high risk of myopathy. Before taking this medication, patients must check for other conditions such as liver disease or hypothyroidism. Symptoms such as muscle pain or weakness may occur; if these are experienced, the doctor should be informed immediately. Additionally, this medication may elevate blood sugar in some patients, so those at risk of diabetes should have their blood sugar levels monitored regularly. It can affect the liver and kidneys, so regular tests of liver function and kidney function are important. Drug efficacy or side effects may vary according to specific genetic factors, so dose adjustments may be necessary. Certain drugs that may interact with this medication must be reported to the doctor or pharmacist. Women who are pregnant or planning pregnancy should not take this medication and should use appropriate contraception, and breastfeeding women should avoid using this medication. In cases of overdose, there is no specific antidote, so appropriate treatment should be conducted based on symptoms, while monitoring liver function and muscle enzyme levels. Lastly, while this medication is unlikely to impair driving or machine operation, caution should be exercised as dizziness may occur.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ophthalmoplegia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, morbilliform drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, elevated ALT, chest pain, muscle cramps, gout, erectile dysfunction, elevated AST, joint pain, fatigue, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and humidity, so it should be stored in a tightly sealed container. The recommended storage temperature is room temperature between 1 and 30 degrees Celsius. Proper storage can help maintain the medication's efficacy for a long time.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

30 tablets/PTP [(10 tablets/PTP x 3)], 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.